FEED Company Profile and Key Details

FEED has shown weak momentum, losing -46.05% over the past week and -79.06% over the past quarter, though year-to-date performance is down -46.75%. Short-term trend indicators are mixed aligned (SMA20 -19.42%, SMA50 -8.7%, SMA200 -65.65%). The stock’s 14-day RSI is 44.95 (neutral), while the ATR of 0.55 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.61% below its high and over 128.28% above its low. Average 10-day trading volume of 3.77 million shares is significantly above the 3-month average of 1.19 million, indicating heightened recent market interest.

ENvue Medical, Inc. generated EPS of -$96.17 over the past year. Five-year average earnings growth is 40.47%.

ENvue Medical, Inc. has 6.09 million shares outstanding. The public float is 6.09 million shares, elevated short interest at 2.69% of float. This equals 161.66 thousand shares. The short ratio is 0.41 days. Institutional investors hold 0.92% of the float. Insiders own 20.92%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

The stock is currently mid-range between its 52-week high and low $0.29 and $5.98. With a market capitalization of about $4.03 million, ENvue Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.56). Headquartered in Tyler, TX, ENvue Medical, Inc. operates in the Healthcare sector and the Medical - Specialties industry. Led by CEO Doron Robert Besser, the company employs approximately 13 people and listed since December 12, 2025. NanoVibronix, Inc. focuses on developing non-surgical medical devices that stimulate biological responses.

ENvue Medical, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 1.83 The P/FCF stands at -0.32, also above market averages.

ENvue Medical, Inc. (NASDAQ:FEED) shares are down -46.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ENvue Medical, Inc. trading at a premium to the broader market with a P/E of -0.0. Our AI forecast model points to short-term strength (11.63% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that ENvue Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.63%, with price expected at $0.48 by September 01, 2026, within a range of $0.45 to $0.52 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by November 16, 2026, with a range of $0.00 to $0.06. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by August 18, 2027, within a range of $0.00 to $0.08.